139 related articles for article (PubMed ID: 37064142)
1. A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma.
Yang Q; Li G; Wu X; Lin H; Wu W; Xie X; Zhu Y; Cai W; Shi C; Zhuo S
Front Oncol; 2023; 13():1136366. PubMed ID: 37064142
[TBL] [Abstract][Full Text] [Related]
2. Effects of Fufang Banmao Capsule Associated with Sorafenib on Liver Function, Immune Status, Quality of Life Improvement, and Survival in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Lai X; Wang A
Comput Intell Neurosci; 2022; 2022():6336107. PubMed ID: 36052044
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy of aparatinib and carrilizumab combined with transcatheter arterial chemoembolization in the treatment of primary hepatocellular carcinoma.
Chen C; Duan XT; Li GY; Hao XJ; Wang WL; Shen YF; Zhang SH
Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4135-4144. PubMed ID: 37203839
[TBL] [Abstract][Full Text] [Related]
4. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
[TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag.
He L; Chen X; Ding L; Zhang X
J Oncol; 2022; 2022():1530875. PubMed ID: 36276277
[TBL] [Abstract][Full Text] [Related]
6. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.
Li X; Zhang Q; Lu Q; Cheng Z; Liu F; Han Z; Yu X; Yu J; Liang P
Front Immunol; 2022; 13():1023983. PubMed ID: 36389778
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen H; Xue L; Liu L; Li P
J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
[TBL] [Abstract][Full Text] [Related]
8. The effect of TACE in combination with thalidomide-mediated adjuvant therapy on the levels of VEGF and bFGF in patients with hepatocellular carcinoma.
Tong C; Liu H; Chen R; Zhu F
Am J Transl Res; 2021; 13(5):5575-5581. PubMed ID: 34150160
[TBL] [Abstract][Full Text] [Related]
9. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
11. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
Front Oncol; 2021; 11():835889. PubMed ID: 35174073
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Yuan G; Cheng X; Li Q; Zang M; Huang W; Fan W; Wu T; Ruan J; Dai W; Yu W; Chen M; Guo Y; Hu X; Chen J
Onco Targets Ther; 2020; 13():12683-12693. PubMed ID: 33328740
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.
Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
Can J Gastroenterol Hepatol; 2022; 2022():7982118. PubMed ID: 35586608
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study.
Zhu D; Ma K; Yang W; Zhou HF; Shi Q; Ren JW; Xie YG; Liu S; Shi HB; Zhou WZ
Front Oncol; 2022; 12():1057560. PubMed ID: 36439471
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study.
Zheng Z; Liu Z; Zhang H; Guo X; Jia X; Wang J; Meng L; Xin Y; Jiang X
Front Pharmacol; 2022; 13():894016. PubMed ID: 35656302
[No Abstract] [Full Text] [Related]
16. [Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].
Yuan GS; He WM; Hu XY; Li Q; Zang MY; Cheng X; Huang W; Ruan J; Wang JJ; Hou JL; Chen JZ
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):326-331. PubMed ID: 33979958
[No Abstract] [Full Text] [Related]
17. Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study.
He W; Liao L; Hu D; Li B; Wang C; Qiu J; Liao Y; Liu W; Yang Z; Zhang Y; Yuan Y; Li K; Yuan Y; Zheng Y
Ann Transl Med; 2020 Aug; 8(16):1000. PubMed ID: 32953800
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma.
Gu H; Li J; You N; Wu K; Wang Z; Wang L; Zhu Y; Liu Q; Peng X; Zheng L
Ann Transl Med; 2020 Dec; 8(24):1677. PubMed ID: 33490189
[TBL] [Abstract][Full Text] [Related]
19. Observation of efficacy of TACE combined with HIFU on patients with middle-advanced liver cancer.
Zhang Q; Bian SQ; Lv W; Kou D; Hu HL; Guo SS; Cao ZS
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):239-246. PubMed ID: 31389607
[TBL] [Abstract][Full Text] [Related]
20. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
